Adaptive Phage Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Adaptive Phage Therapeutics, Inc. - overview
Established
2016
Location
Gaithersburg, MD, US
Primary Industry
Biotechnology
About
Founded in 2016 by Carl Merril MD and Gregory Merril and based in Maryland, US, Adaptive Phage Therapeutics, Inc. operates as a biotechnology company that offers a therapeutic response for patients with multi-drug-resistant (MDR) pathogenic bacteria. In March 2024, BiomX Inc. , a portfolio company of Mirae Asset Global Investments, Deerfield Management, RTW Investments, Nantahala Capital Management, Cystic Fibrosis Foundation, OrbiMed Advisors, and AMR Action Fund, acquired Adaptive Phage Therapeutics, Inc.
from Mayo Clinic, Deerfield Management, and AMR Action Fund. The company’s primary product, PhageBank™, addresses this challenge by utilizing an expanding library of bacteriophages, or phages, which offer broad-spectrum and polymicrobial coverage against resistant bacteria. The PhageBank™ phages are selected using a proprietary phage susceptibility assay developed in collaboration with Mayo Clinic Laboratories.
Current Investors
Alexandria Venture Investments, U.S. Department of Defense, Mayo Clinic
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.